- Home
- FLC vs CGTX Comparison
FLC vs CGTX Comparison
Compare FLC & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLC
- CGTX
- Stock Information
- Founded
- FLC 2003
- CGTX 2007
- Country
- FLC United States
- CGTX United States
- Employees
- FLC N/A
- CGTX N/A
- Industry
- FLC Trusts Except Educational Religious and Charitable
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- FLC Finance
- CGTX Health Care
- Exchange
- FLC Nasdaq
- CGTX Nasdaq
- Market Cap
- FLC 186.8M
- CGTX 158.8M
- IPO Year
- FLC N/A
- CGTX 2021
- Fundamental
- Price
- FLC $17.60
- CGTX $1.67
- Analyst Decision
- FLC
- CGTX Strong Buy
- Analyst Count
- FLC 0
- CGTX 3
- Target Price
- FLC N/A
- CGTX $2.83
- AVG Volume (30 Days)
- FLC 37.8K
- CGTX 1.4M
- Earning Date
- FLC 01-01-0001
- CGTX 11-06-2025
- Dividend Yield
- FLC 6.64%
- CGTX N/A
- EPS Growth
- FLC N/A
- CGTX N/A
- EPS
- FLC N/A
- CGTX N/A
- Revenue
- FLC N/A
- CGTX N/A
- Revenue This Year
- FLC N/A
- CGTX N/A
- Revenue Next Year
- FLC N/A
- CGTX N/A
- P/E Ratio
- FLC N/A
- CGTX N/A
- Revenue Growth
- FLC N/A
- CGTX N/A
- 52 Week Low
- FLC $12.62
- CGTX $0.22
- 52 Week High
- FLC $15.45
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- FLC 46.60
- CGTX 49.79
- Support Level
- FLC $17.46
- CGTX $1.54
- Resistance Level
- FLC $17.76
- CGTX $1.83
- Average True Range (ATR)
- FLC 0.15
- CGTX 0.14
- MACD
- FLC -0.01
- CGTX -0.01
- Stochastic Oscillator
- FLC 33.75
- CGTX 36.25
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.